Elysium Health Secures $40 Million Series C Funding to Expand Clinically Validated Health Supplement Portfolio

VCBeat (WeChat ID: vcbeat) learned from foreign media that Elysium Health has completed a $40 million Series C financing round. The round was led by GISEV Family Ventures, with participation from Mayo Clinic Ventures and leading venture capital firm Western Technology Investment. Returning investors included General Catalyst, Morningside Ventures, and Breyer Capital.

Elysium Health was founded in 2014 by biologists Leonard Guarente, Dan Alminana, and Eric Marcotulli, with a focus on marketing dietary supplements and other health products. Elysium Health states that its core products can help improve sleep, repair DNA, and promote longer, healthier lives. The Elysium Health team comprises scientists, engineers, and innovators, along with a Scientific Advisory Board consisting of eight Nobel laureates and leading experts from various fields. Elysium’s product development process spans from research and development to clinical studies, culminating in human clinical trials that demonstrate the safety and efficacy of its products.

It is reported that since its establishment in 2014, Elysium Health has raised approximately $72.1 million in funding, having secured Series A and Series B financing in 2015 and 2016, respectively.

This financing will support the expansion of Elysium Health’s supplement portfolio and product lines (which currently include tested and clinically validated interventions), the continued growth of its customer base, and additional human clinical trials to assess the safety and efficacy of both new and existing products. Since its inception, Elysium Health has been widely recognized for its commitment to scientific rigor, and this funding will further advance the company’s long-standing mission to enable more consumers to benefit from scientific research.

Eric Marcotulli, CEO of Elysium Health, stated, “It is our honor to collaborate with the world’s leading healthcare investors. Partners who support innovation, employ scientifically rigorous product development approaches, and uphold superior quality are vital to us. We look forward to working with our financial partners and our Scientific Advisory Board to further expand our product portfolio, thereby fulfilling our mission of bringing meaningful health products to market.”

Giammaria Giuliani of GISEV Family Ventures stated, “My family has been active in the healthcare sector since 1889. Over the past decade, we have made substantial investments in pharmaceutical intellectual property and have emerged as a global leader in this field. We have consistently sought out companies that are pioneering new frontiers in healthcare, and Elysium Health’s approach to product development particularly caught my attention. With innovation at the core of their strategy, they place strong emphasis on product launches, and their internal standards for quality and clinical testing are gradually becoming industry benchmarks. We are delighted to invest in the Elysium Health team.”

GISEV Family Ventures is an investment firm based in Lugano, Switzerland.

Mayo Clinic Ventures is dedicated to promptly assisting patients with serious illnesses. The Mayo Clinic Ventures team works closely with Mayo Clinic physicians and scientists to uncover inventions, ideas, and discoveries that will truly transform healthcare. The Mayo Clinic Ventures team provides substantial financial support for Mayo’s patient care, education, and research.

(Compiled by: Chang Jia)